DEPO-SUBQ PROVERA 104 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depo-subq Provera 104, and what generic alternatives are available?
Depo-subq Provera 104 is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depo-subq Provera 104
A generic version of DEPO-SUBQ PROVERA 104 was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEPO-SUBQ PROVERA 104?
- What are the global sales for DEPO-SUBQ PROVERA 104?
- What is Average Wholesale Price for DEPO-SUBQ PROVERA 104?
Summary for DEPO-SUBQ PROVERA 104
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 59 |
| Patent Applications: | 4,276 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | DEPO-SUBQ PROVERA 104 at DailyMed |
Recent Clinical Trials for DEPO-SUBQ PROVERA 104
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oregon Health and Science University | Early Phase 1 |
| Canadian Cancer Society (CCS) | Phase 4 |
| University of British Columbia | Phase 4 |
Pharmacology for DEPO-SUBQ PROVERA 104
| Drug Class | Progestin |
US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPO-SUBQ PROVERA 104
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEPO-SUBQ PROVERA 104
See the table below for patents covering DEPO-SUBQ PROVERA 104 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 100473376 | ⤷ Sign Up | |
| China | 1429101 | ⤷ Sign Up | |
| Japan | 4205341 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0113964 | 97C0037 | Belgium | ⤷ Sign Up | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
